Nature's issue: CD4+ T cells have this protein on the surface and have the strongest anti-cancer ability! December 22, 2017 Source: Bio Discovery Nowadays, "adoptent cell transfer" is one of the most effective ways to treat melanoma and many blood cancers, but it is not very effective against invasive solid tumors such as pancreatic cancer. This is mainly because there are hundreds of T cells in the human body, and it is very difficult to identify good "anti-cancer fighters". An article in the December issue of Nature Communications brought good news. The researchers found that T cells with CD26 protein on the surface have the strongest anticancer activity. 1 , CD4 + T cells : new anti-cancer warriors The study was led by Dr. Chrystal Paulos of the Hollings Cancer Center at the Medical University of South Carolina (MUSC). The findings began with the team's observation of a group of T cells that have not been widely used in ACT. We know that there are many different families of T cells, most of which use CD8+ T cells, while the Paulos team chooses to focus on CD4 cells. Stefanie Bailey, a lead author of the paper and a postgraduate from the Paulos team, explained that CD4+ T cells are often overlooked in cancer immunotherapy and that people are more likely to choose CD8+ T cells with strong anticancer properties. While CD4+ T cells are primarily known to help other cells function - in fact, CD4 + T cells are also known as "T-helper cells," and later studies have shown that it also clears cancer. 2 , CD26 protein: enhance anti-cancer effect In the spring of 2016, the team discovered a special CD4 + T cell, Th17 cells, which is very effective against invasive solid tumors. But you need to find a way to screen them for treatment. Subsequently, a new study caught the attention of Bailey, a protein on the surface of the T cell called CD26 that carries a marker for Th17. CD26 is a multifunctional protein located on the cell surface and is well known in the field of immunology. Although well known, Paulos's research team was the first to study its role in anti-cancer. They found that all CD4 + T cells had different levels of CD26 on their surface and their ability to fight cancer was different. Preliminary trials have led researchers to believe that T cells with high CD26 levels are the least effective against cancer. However, as we go further, the result is exactly the opposite. The team found that these cells not only kill a variety of solid tumors, but also survive in patients for a long time. This shows that CD26 high-level T cells are actually excellent anti-cancer fighters. Researchers have been trying to find multiple markers to identify the best T cells. Now, this breakthrough study shows that the marker only needs to lock CD26. 3 , clinical significance is exciting The researchers studied melanoma, mesothelioma, and pancreatic cancer, and found that animal models carrying these tumor types were more effective when CD26 donor T cells were 100% infiltrated. Among them, melanoma has a cure rate of 50%, and mesothelioma has a cure rate of 95%. Pancreatic cancer has no curative response, but the tumor size is reduced by two-thirds and the survival of the preclinical model is extended. These findings suggest that CD26 donor T cells may be more effective in combination therapy. Dr. Chrystal Paulos, source: MUSC Paulos said that we are excited about the broader clinical significance of this finding. CD26-targeted T cells are not only beneficial for ACT treatment, but also help to enhance other cancer immunotherapies (such as checkpoint inhibitors, vaccines, and cytokine therapy). ) effectiveness. In addition, CD4 + T cells express different levels of CD26 and can also be used to treat patients with infectious diseases and autoimmune manifestations. Now, Paulos Labs is working with MUSC and researchers around the world to further investigate the role of CD4+ T cells with different levels of CD26 in different types of cancer and autoimmune diseases. In addition to providing more effective treatment, CD4 + T cells can also help patients reduce costs and treatment time. References: 1) Overlooked immune cells hold breakthrough for treating aggressive cancers Dingmin Pharmaceutical supply Velpatasvir API and Velpatasvir Intermediates with high purity and best price. The main products CAS No are as follows: 1377049-84-7, 1378388-16-9, 1335316-40-9, 1438383-89-1. Sample can be sent if you request. Cas 1335316-40-9,Velpatasvir Intermediates,11-Dihydro-5H-Dibenzo Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com
Welcome to do business with us. Please email to us directly.